Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD.
作者信息
Roche Meaghan, Sawinski Deirdre L, Cohen Jordana B
机构信息
Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
出版信息
Kidney Med. 2019 Jul 13;1(4):150-152. doi: 10.1016/j.xkme.2019.07.001. eCollection 2019 Jul-Aug.
Abstract
摘要
相似文献
1
Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD.促进丙型肝炎病毒和慢性肾脏病患者围绕直接抗病毒药物治疗时机的以患者为中心的决策制定。
Kidney Med. 2019 Jul 13;1(4):150-152. doi: 10.1016/j.xkme.2019.07.001. eCollection 2019 Jul-Aug.
2
Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.丙型肝炎直接作用抗病毒药物时代的高危供肝肝移植。
Exp Clin Transplant. 2020 Oct;18(5):605-611. doi: 10.6002/ect.2019.0065. Epub 2019 Jul 19.
3
Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease.用于治疗慢性肾脏病患者慢性丙型肝炎的直接抗病毒药物。
Therap Adv Gastroenterol. 2016 Nov;9(6):887-897. doi: 10.1177/1756283X16665254. Epub 2016 Sep 14.
4
Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals.慢性肾病患者的抗丙型肝炎病毒治疗可提高长期肾脏存活率和患者存活率。
World J Clin Cases. 2019 Jun 6;7(11):1270-1281. doi: 10.12998/wjcc.v7.i11.1270.
5
Treatment and management options for the hepatitis C virus infected kidney transplant candidate.丙型肝炎病毒感染的肾移植候选者的治疗与管理方案
Hemodial Int. 2018 Apr;22 Suppl 1:S36-S44. doi: 10.1111/hdi.12646.
6
Hepatitis C in Chronic Kidney Disease: An Overview of the KDIGO Guideline.慢性肾脏病中的丙型肝炎：KDIGO 指南概述。
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2158-2167. doi: 10.1016/j.cgh.2019.07.050. Epub 2019 Jul 31.
7
A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment.一种用于丙型肝炎病毒和慢性肾脏病治疗的患者决策支持工具。
Kidney Med. 2019 Jul 11;1(4):200-206. doi: 10.1016/j.xkme.2019.06.003. eCollection 2019 Jul-Aug.
8
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
9
A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.用于治疗晚期慢性肾病患者丙型肝炎的直接抗病毒药物综述。
Nephrol Dial Transplant. 2017 Jan 1;32(1):35-41. doi: 10.1093/ndt/gfv361.
10
The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.接受直接作用抗病毒药物治疗的大多数丙型肝炎患者存在发生相关药物相互作用的风险。
United European Gastroenterol J. 2017 Aug;5(5):648-657. doi: 10.1177/2050640616678151. Epub 2016 Nov 4.
本文引用的文献
1
A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment.一种用于丙型肝炎病毒和慢性肾脏病治疗的患者决策支持工具。
Kidney Med. 2019 Jul 11;1(4):200-206. doi: 10.1016/j.xkme.2019.06.003. eCollection 2019 Jul-Aug.
2
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.奥比他韦/帕利瑞韦/利托那韦治疗丙型肝炎病毒1型或4型感染合并晚期肾病患者的疗效与安全性
Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
3
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease.ombitasvir、paritaprevir、利托那韦和达沙布韦联合或不联合利巴韦林用于肾病患者的治疗
Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
4
Safety and Efficacy of Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir for Hepatitis C Virus Infection Across All Levels of Kidney Function.帕立普瑞韦/利托那韦、奥比他韦和达沙布韦治疗不同肾功能水平丙型肝炎病毒感染的安全性和有效性
Kidney Int Rep. 2018 Dec 1;4(2):191-193. doi: 10.1016/j.ekir.2018.11.018. eCollection 2019 Feb.
5
Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.丙型肝炎病毒血清阳性维持性透析患者的死亡率和肾移植结局：一项回顾性队列研究。
Am J Kidney Dis. 2019 Jun;73(6):815-826. doi: 10.1053/j.ajkd.2018.11.009. Epub 2019 Jan 29.
6
Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus.艾滋病毒感染者肾移植供体获得机会不均等。
Clin Transplant. 2019 Feb;33(2):e13466. doi: 10.1111/ctr.13466. Epub 2019 Jan 12.
7
The association of hepatitis C infection with the onset of CKD and progression into ESRD.丙型肝炎感染与慢性肾脏病的发生及进展为终末期肾病的关联。
Semin Dial. 2019 Mar;32(2):108-118. doi: 10.1111/sdi.12759. Epub 2018 Nov 29.
8
Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation.肾移植前后丙型肝炎治疗的人群结局和成本效益。
Am J Transplant. 2018 Oct;18(10):2483-2495. doi: 10.1111/ajt.15040. Epub 2018 Aug 30.
9
The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.直接作用抗病毒药物对肝、肾移植成本和结局的影响。
Am J Transplant. 2018 Oct;18(10):2473-2482. doi: 10.1111/ajt.14895. Epub 2018 May 29.
10
Timing of hepatitis C virus infection treatment in kidney transplant candidates.肾移植候选者中丙型肝炎病毒感染的治疗时机
Hemodial Int. 2018 Apr;22 Suppl 1:S61-S70. doi: 10.1111/hdi.12643.
Zotero 插件